Medicine and Dentistry
Lupus Nephritis
100%
Systemic Lupus Erythematosus
76%
Lupus Erythematosus
50%
Medicine
45%
Transcriptomics
36%
Proteinuria
34%
Renal Biopsy
29%
Fibrosis
24%
Scleroderma
24%
Creatinine
24%
Topoisomerase
22%
Proteomics
22%
Immunology
22%
Keratinocyte
22%
Biopsy
18%
T-Helper Cell
17%
Interstitial Lung Disease
15%
Kidney Injury
14%
Disease
14%
Biological Marker
14%
Interferon Type I
12%
Glomerular Filtration Rate
12%
Immunocompetent Cell
12%
Immunosuppressive Drug
12%
COVID-19 Vaccination
11%
Raynaud Phenomenon
11%
Adverse Event
11%
Mesangial Proliferative Glomerulonephritis
11%
Acroosteolysis
11%
Subacute Cutaneous Lupus Erythematosus
11%
End Stage Renal Disease
11%
Immunoglobulin
11%
Antibody Response
11%
Interleukin 16
11%
Pericarditis
11%
Phenotype
11%
Intravenous Immunoglobulin Therapy
11%
Fasudil
11%
Rilonacept
11%
Kidney Function
11%
Lichen Myxedematosus
11%
Rho Kinase Inhibitor
11%
Anifrolumab
11%
Lipoprotein
11%
Epitope
11%
Clinical Management
11%
Membranous Glomerulonephritis
11%
Rheumatology
8%
Skin Temperature
7%
Urinary System
6%
Keyphrases
Lupus Nephritis
94%
Systemic Lupus Erythematosus
67%
Lupus
38%
Single-cell Transcriptomics
36%
Kidney
27%
Scleroderma
22%
Topoisomerase
22%
Tubular Cells
22%
Fibrosis
22%
Immune Landscape
22%
Urine Proteome
22%
Immunology
22%
Keratinocytes
22%
Epitope
22%
Kidney Biopsy
21%
COVID-19 Infection
18%
Interstitial Lung Disease
16%
Estimated Glomerular Filtration Rate
14%
Standard-of-care Therapy
14%
COVID-19 Vaccination
14%
Clinically Indicated
14%
Type I Interferon
14%
Autoantibodies
14%
COVID-19 Risk
13%
Autoimmune Connective Tissue Diseases
13%
Renal Damage
13%
Rheumatoid Arthritis
13%
Hydroxychloroquine
12%
Complete Responders
11%
Surnames
11%
Longitudinal Predictors
11%
Granzyme B
11%
Membranous Nephritis
11%
Membranoproliferative Glomerulonephritis
11%
Complement Levels
11%
Acro-osteolysis
11%
End-stage Kidney Disease
11%
Longitudinal Patterns
11%
Sex-specific
11%
University Schools
11%
Response Pattern
11%
School of Medicine
11%
Immunosuppressive Agents
11%
Rho Kinase Inhibitor Fasudil
11%
IgG Levels
11%
Human Herpesvirus 6 (HHV-6)
11%
Long Non-coding RNA (LncRNA)
11%
Adverse Events
11%
Pericarditis
11%
Diagnosis Management
11%
Immunology and Microbiology
Lupus Erythematosus
69%
Nephritis
58%
Systemic Lupus Erythematosus
55%
Systemic Scleroderma
41%
Scleroderma
40%
T Cell
28%
Epitope
22%
T-Helper Cell
21%
Autoimmune Disease
21%
Monospecific Antibody
19%
interferon
17%
Blood Level
15%
Autoantibodies
15%
Immune Response
13%
Connective Tissue
13%
B Cell
13%
Transcriptomics
13%
Interleukin 16
13%
Hydroxychloroquine
12%
Inflammatory Arthritis
12%
Immunocompetent Cell
12%
Raynaud Phenomenon
11%
Osteoclastogenesis
11%
Granzyme B
11%
Toll-Like Receptor
11%
Intravenous Immunoglobulin Therapy
11%
Kidney Transplantation
11%
Vasculotropin
11%
Glomerulus Filtration
11%
Human Herpesvirus 6
11%
Phenotype
11%
Pericarditis
11%
Protein Degradation
11%
Cell Population
11%
Rilonacept
11%
Intravenous Immunoglobulin
11%
Glomerulonephritis
11%
Skin Temperature
11%
Gene Expression
7%
Peripheral Blood Mononuclear Cell
7%
Monocyte
7%
Epstein Barr Virus
6%
Antigen Presentation
6%
Autoantigen
6%
RNA Sequence
6%
Cytokine
5%
Blood Flow
5%
Transforming Growth Factor
5%
Leukocyte
5%
Inflammation Response
5%
